AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00810992 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional and behavioral program A
Description: Recommendation for nutrition and behavior for patients with coronary artery disease according to the German Society of Nutritional Medicine and the International Task Force for the Prevention of Coronary Artery Disease
Study NCT00810992 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional and behavioral program B
Description: Recommendation for nutrition and behavior for patients with coronary artery disease according to the system of the Traditional Tibetan Medicine
Study NCT04558021 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10ml placebo(absent of niclosamide)
Study NCT01439399 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine,
Description: Lidocaine group received an IV bolus of 1.5 mg.kg-1 followed by a continuous infusion of 2 mg.kg-1.h-1 intraoperative and 1.33 mg.kg-1.h-1 for 48 h postoperative.
Study NCT01439399 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Ketamine group received a bolus of 0.5 mg.kg-1, then 0.25 mg.kg-1.h-1 followed by 0.1 mg.kg-1.h-1 for the first 24 h, then 0.05 mg.kg-1.h-1 for the next 24 h.
Study NCT03997110 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short course palliative radiation.
Description: Week 1: Patients in the experimental arm will be treated with short course radiotherapy (25Gy/5#). The dose fractionation of 25 Gy in 5# over a week will be used. Week 4: Patients who have almost complete clinical response will be evaluated for brachytherapy will receive the appropriate brachytherapy procedure depending on the tumor response to a dose of 6-8Gy x 2-3#. The patients who will be found unsuitable for brachytherapy will be kept under observation. Week 12: After treatment completion, response assessment will be done using following parameters: • Pain assessment using numerical pain rating scale on 0-10 • Vaginal bleeding- yes/no • Vaginal discharge- yes/ no • Analgesic use- WHO ladder and dosing • QOL QC30, QLQC15 Pall, QLQC Cervix 24 • Disease response • Acute toxicity. Follow up: Patients follow up will be utilizing standard of care imaging and lab investigations used for the patients. Patients will be evaluated every 3 months for the study duration.
Study NCT03997110 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Long course palliative treatment.
Description: Week1: All the patients will receive external sitting of radiation treatment, first fraction of 10 Gy. Week4: All the patients will receive external sitting of radiation treatment, second fraction of 10 Gy. Week7: Patients who have almost complete clinical response will be evaluated for brachytherapy will receive the appropriate brachytherapy procedure depending on the tumor response to a dose of 6-8Gy x 2-3#.The patients who will be found unsuitable for brachytherapy will receive another sitting of external radiation, third fraction of 10 Gy. Week 12: After treatment completion response assessment will be done using following parameters: • Pain assessment using numerical pain rating scale on 0-10 • Vaginal bleeding- yes/ no • Vaginal discharge- yes/no • Analgesic use- WHO ladder and dosing • QOL QC30, QLQC15 Pall, QLQC Cervix 24 • Disease response • Acute toxicity
Study NCT03802591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS1001 monoclonal antibody
Description: Participant will receive CS1001 monoclonal antibody by intravenous infusion every 3 weeks(Q3W), for up to 24 months
Study NCT03802591 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CS1001 placebo
Description: Participant will receive CS1001 placebo antibody by intravenous infusion every 3 weeks(Q3W), for up to 24 months
Study NCT03802591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Administered as an IV infusion on Day 1 Q3W
Study NCT03802591 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxaliplatin
Description: Administered as an IV infusion on Day 1 Q3W
Study NCT03802591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Administered by oral, twice a day on Day 1 - Day 14 of each cycle.
Study NCT03802591 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capecitabine
Description: Administered by oral, twice a day on Day 1 - Day 14 of each cycle.
Study NCT02597387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone HCL Liposome Injection
Study NCT03361982 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Slow Freezing and Thawing
Description: half of the surgically obtained testicular sperm will be frozen for 30 minutes and subsequently thawed prior to performing ICSI
Study NCT03025243 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: computer aided surgical guide
Description: comparing accuracy of surgical guide of printing layer thickness of 50 micron and 100 micron by superimposition of pre-operative and post-operative CBCT
Study NCT03025243 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: computer aided surgical guide
Description: comparing accuracy of surgical guide of printing layer thickness of 50 micron and 100 micron by superimposition of pre-operative and post-operative CBCT
Study NCT01619176 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: 30 minutes acupuncture every other day for 3 months.~Basic acupoints: Zusanli, st36; Taixi，KI3）; Shenxu, BL23 Additional acupoints due to personal condition: Waiguan，SJ5; Baxie，Ex-UE9;Yinlingquan，(SP9）; Quchi，LI11; Yanglingquan，GB34; Xuehai，SP10; Dazhu，BL11; Dazhui，DU14; Pixu，BL20.
Study NCT00519597 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ResMed S8 (Auto-CPAP)
Description: AutoCPAP during sleep
Study NCT00519597 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ResMed S8 (Auto-CPAP)
Description: AutoCPAP during sleep
Study NCT02406131 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Remote Ischemic Preconditioning
Description: standard blood pressure cuffs applied to upper limb . The cuff will be inflated to 200 mmHg applied for 5 minutes alternating with 5 minutes rest to the total of 4 cycles
Study NCT04320901 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ligasure
Description: Ligasure™ Maryland Jaw Laparoscopic Sealer/Divider 37cm
Study NCT04320901 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Harmonic
Description: Harmonic ACE 7+
Study NCT01418742 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Panitumumab, Doxycycline/Placebo
Description: comparison of Doxycyline/Placebo and Panitumumab regarding efficacy of the therapy of panitumumab induced skin toxicity
Study NCT01418742 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Panitumumab
Description: mCRC patients receiving panitumumab as EGFR inhibitor.
Study NCT01291407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1,30mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner.
Study NCT01291407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1,40mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner.
Study NCT00544674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PR104
Description: administered at a dose of 1100 mg/m\^2 by intravenous infusion over 1 hour and repeated every three weeks
Study NCT01291407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1,50mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner
Study NCT01291407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1,60mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner.
Study NCT01291407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1,70mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner.
Study NCT01291407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1,80mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner.
Study NCT00544674 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: F-18-fluoromisonidazole
Description: administered intravenously prior to PET scan
Study NCT01439399 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: association ketamine-lidocaine
Description: Ketamine-lidocaine group received a bolus of 1.5 mg.kg-1 of lidocaine and 0.5 mg.kg-1 of ketamine, a continuous infusion of 1.3 mg.kg-1.h-1 of lidocaine and 0.17 mg.kg-1.h-1 of ketamine was delivered followed by 0.9 mg.kg-1 of lidocaine with 0.08 mg.kg-1.h-1 of ketamine during 48 h, the dose of ketamine being reduced to 0.04 mg.kg-1.h-1 after the first 24 hours.
Study NCT01439399 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The control group (C) received an equal volume of saline 0.9 % during 48 h.
Study NCT02895074 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Femtosecond laser-assisted cataract surgery
Description: A femtosecond laser (Alcon-Lensx, Alcon-Lensx, Inc.) was used in this study. After pupil dilation and topical anesthesia, the laser was docked to the eye using a curved contact lens to applanate the cornea. With the integrated OCT imaging system, the locations of the cornea and the anterior and posterior surfaces of the crystalline lens were determined. A 5.0-mm-diameter capsulotomy was created by scanning a cylindrical pattern and followed by lens fragmentation. The laser was disconnected, and the remainder of the surgery was performed as phacoemulsification (Infiniti® Vision System; Alcon, USA). Folded intraocular lenses (IOLs) were implanted in the capsular bags.
Study NCT02895074 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional phacoemulsification cataract surgery
Description: Phacoemulsification was performed through a temporal 3.2-mm clear corneal incision with the same machine and followed by IOLs implantation.
Study NCT03319212 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: senofilcon A contact lenses
Description: Senofilcon A Daily Disposable Contact Lenses
Study NCT00761722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: Arm 1:~Cycle 1 (PK Phase) - Subjects will receive a single SC dose of 75 mg/m2 on Days 1 and 15. Single oral doses of a given formulation of azacitidine will be administered in increasing doses on Days 3 and 5, and at doses calculated to deliver 80% and 120% of the SC exposure, up to a maximum dose of 600 mg on Days 17 and 19.~Cycles 2 and beyond - (Treatment phase) Oral azacitidine will be administered in a dose calculated to deliver 100% of the SC exposure up to a maximum of 600 mg on days 1 - 7 of a 28 day cycle.~Arm 2:~All Cycles - Oral azacitidine will be administered a maximum of 600 mg on Days 1 - 7 of a 28 days cycle.
Study NCT00718705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Josamycin
Description: josamycin with posology of 2 grams per day by oral way during 10 days
Study NCT00718705 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo with posology of 2 grams per day by oral way during 10 days
Study NCT01653990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxifloxacin
Description: oral dose of 400mg moxifloxacin
Study NCT01653990 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: moxifloxacin
Description: oral dose of 400mg moxifloxacin
Study NCT01653990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxifloxacin-placebo
Description: Oral dose of a pill of moxifloxacin-placebo
Study NCT01653990 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: moxifloxacin-placebo
Description: Oral dose of a pill of moxifloxacin-placebo
Study NCT01895959 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Euflexxa
Description: Euflexxa will be injected weekly for 3 consecutive weeks on the knee joint.
Study NCT01895959 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Magnetic Resonance Imaging (MRI)
Description: MRI of the knee will be acquired during baseline (a week prior to the treatment), follow up visit 1 (1 week after treatment) and follow up visit 2 (3 months after treatment).
Study NCT00397436 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: UV Irradiation
Description: UV irradiation
Study NCT03116256 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Very low calorie diet (VLCD)
Description: All participants (including exercise group) will be using full daily meal replacement during the 6-week interventional period. The total meal supplement is 600 kcal/day.
Study NCT03116256 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Very low calorie diet (VLCD)
Description: All participants (including exercise group) will be using full daily meal replacement during the 6-week interventional period. The total meal supplement is 600 kcal/day.
Study NCT03116256 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High intensity interval training (HIIT)
Description: Participants in this group will be having HIIT session three times per week under close medical supervision. This involves 60 sec high intensity cycling at 95-125% Watt Max, with 90s recovery, repeated 5 times, with 2 minutes warm up and cool down.
Study NCT03792672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: TAK-653 placebo-matching tablets.
Study NCT03116256 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance exercise training (RET)
Description: The exercise format will be 2 sets of 12 repetitions at 70% 1-RM for each resistance regime, with 1-2 minutes rest between sets after a prescribed warm-up 3 sessions/week. The resistance regimes are: (3 upper body)chest press, latissimus pull down, seated lever row; (3 lower body) leg extension, leg curl, leg press. Participants will be alternating between upper and lower body exercise during each training session.
Study NCT05002179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Echinaforce Chewable tablets
Description: Preventive treatment: 3X2 EC tablets daily during 2 + 2 months of prevention after run-in of 1 week and intermittent treatment break of 1 week without treatment + 1 month of voluntary follow-up prevention.~Acute treatment: 5 X 2 EC tablets daily for max. 10 days per individual vRTI or until symptom resolution.
Study NCT02728466 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Flavanol and procyanidin supplement
Description: Sustained intake (2x daily over 1 month) of a cocoa-based supplement containing flavanols (monomers) and procyanidins (dimers to decamers)
Study NCT02728466 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Procyanidin-containing supplement
Description: Sustained intake (2x daily over 1 month) of a cocoa-based supplement containing procyanidins (dimers to decamers)
Study NCT02728466 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: control supplement deprived of flavanols and procyanidins
Description: Placebo comparator: flavanol and procyanidin deprived supplement Sustained intake (2x daily over 1 month) of a macro-and micronutrient matched supplement
Study NCT01135095 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-dose imaging
Description: The study is designed to assess the validity of a low dose (\~5mSv) Tc99m one day protocol using D-SPECT standard protocol as the comparators.~D-SPECT cardiac scanner the D-SPECT system uses a solid-state detector, made of an alloy of Cadmium, Zinc, and Telluride, eliminating the need for thick crystals and large photomultiplier tubes. As a result, the system is significantly miniaturized, and ergonomically optimized to both user and patient
Study NCT01052077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-34712
Description: Tablets, Oral, 1 - 3 mg OPC-34712
Study NCT01052077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT01052077 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02895074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tropicamide
Description: After pupil dilation, 1 drop of tropicamide (0.5%) was applied every 15 minutes for 3 applications
Study NCT02895074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proparacaine hydrochloride
Description: topical anesthesia with proparacaine hydrochloride (0.5%) was applied.
Study NCT02579889 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DDD+CLS
Description: Device will be programmed in a dual-chamber DDD pacing mode with the Closed Loop Stimulation (CLS) function ON
Study NCT02579889 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DDD(R)
Description: Device will be programmed in a dual-chamber DDD(R) pacing mode with the Closed Loop Stimulation (CLS) function OFF
Study NCT03490006 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block
Description: A relatively recent alternative to the paravertebral block is the thoracic erector spinae plane block, which involves the ultrasound-guided injection of local anesthetic into the interfascial plane deep to the erector spinae muscle at the level of the transverse process. It results in a loss of somatic sensory sensation across multiple unilateral dermatomes due to local anesthetic mediated blockade of the dorsal and ventral rami of the spinal nerve roots. It is increasingly being used due to ease of placing the block and a perception of greater safety. It has been shown to provide pain relief from rib fractures, thoracotomy, and chronic neuropathic pain of the chest wall. However, to date, erector spinae plane block has not been compared with paravertebral block in regards to analgesia with mastectomy surgery, which has been extensively studied.
Study NCT01052077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADT
Study NCT01052077 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ADT
Study NCT03408964 — intervention group
Intervention type: OTHER
Intervention: biological samples collection and analysis
Description: Participants to the study will be assigned to 4 cohorts according to the stage of disease and planned antitumor treatment at time of study entry; they will be followed up and sampled according to a defined time schedule
Study NCT03490006 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Paravertebral Block
Description: Paravertebral block is a classic regional anesthesia technique that has been in use for over 100 years. It is performed by the injection of local anesthetic into the space between the costotransverse ligament and parietal pleura resulting in blockade of ipsilateral intercostal nerves. It results in a loss of somatic sensation over multiple unilateral dermatomes.
Study NCT03400748 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RF Ablation
Description: The intervention consists of a bronchoscopic approach to ablate lung tumors with radio-frequency energy.
Study NCT01818999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IXABEPILONE
Description: injection
Study NCT03514966 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Position change group
Description: Right after ingesting 5 g dimethicone mixed with 100 ml water, subjects in the position change group will be instructed to repeatedly change the body position according to a pre-specified protocol for a period of 15 min: in the order of supine to the left lateral position to prone, left lateral, supine, right lateral, and repeat last four positions twice, each for 1 min; finally supine for 1 min. Thirty and 40 min after dimethicone administration, subjects in both groups will additionally take 200 ml and 800 ml water, respectively before undergoing MCE examination.
Study NCT03953326 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HeartPhone app
Description: Evaluative conditioning (temporally distributed micro-doses presented upon activation of smartphone screen)
Study NCT03953326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcholine
Description: Endothelium-dependent vasodilation is tested with the localized delivery of the neurotransmitter
Study NCT03953326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Nitroprusside
Description: Endothelium-independent vasodilation is tested with the localized delivery of the nitric oxide donor
Study NCT03953326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Arginine, N2-((4-Methylphenyl)Sulfonyl)-, Methyl Ester
Description: This nitric oxide inhibitor is continuously given during the localized delivery of the endothelium-dependent agonist acetycholine.
Study NCT02407639 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CO2
Description: gas
Study NCT02407639 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: air
Description: air
Study NCT00317694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fermagate
Description: Film coated tablet 500mg
Study NCT00317694 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration, film coated tablet, 0mg
Study NCT02481869 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Arthrocentesis/PRP
Description: PRP (n=20): single intra-articular injection of 5 ml of a leukocyte-reduced platelet rich plasma (ACP, Arthrex, Naples, FL) at the time of closed reduction and initial stabilization using ankle-spanning external fixation